Valneva SE - Special Call Transcript
Good day, and thank you for standing by. Welcome to the Valneva Reports VLA2001 Cov-Compare Topline Results. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Thomas Lingelbach, CEO of Valneva. Please go ahead.
Thank you, and good day to everyone. A very warm welcome to our webcast related to our exciting VLA2001 Cov-Compare topline results. On today's call, I'm being accompanied by the trial's Chief Investigator, Adam Finn, Professor of Paediatrics at the University of Bristol. Thanks a lot for making time for that, Adam, much appreciated.
Yes, so you know that Valneva VLA2001 vaccine candidate is the only inactivated whole virus vaccine candidate against COVID in development in Europe today. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |